Skip to content

Study · Case report or series · n = 1 · 2018

7 results

Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection.

Hsu EA, Miller JL, Perez FA, Roth CL

The Journal of clinical endocrinology and metabolism1 Feb 2018Cited by 74 (Europe PMC)

PMID29220529 (opens in a new tab)DOI10.1210/jc.2017-02080 (opens in a new tab)PepBankPUB-29220529
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 13-year-old boy with hypothalamic obesity after craniopharyngioma resection, intranasal oxytocin alone lowered the BMI z score from 1.77 to 1.49 over 10 weeks.

    In plain wordsIn one boy with hypothalamic obesity, oxytocin alone was followed by a lower BMI z score over 10 weeks.

    Peptide
    Oxytocin
    Outcome
    DecreaseBMI z score change, phase 1
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · intranasal · 10 weeksAs given in this study (human).

    Measurements

    BMI z score
    1.77 z score
    baseline
    BMI z score
    1.49 z score
    after 10 weeks of oxytocin

    Source sentences

    Summary
    reduction in body mass index (BMI) z score from 1.77 to 1.49 over 10 weeks during phase 1
    1 context sentence
    Summary · context
    In this parent-observed study, we tested the administration of intranasal OT for 10 weeks (phase 1), followed by a combination of intranasal OT and NAL for 38 weeks (phase 2) in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia post-CP resection.
  2. 02HumanCase report or seriesEfficacy outcome

    In a boy with hypothalamic obesity, hyperphagia was reduced during oxytocin alone (phase 1); the abstract states this jointly for phases 1 and 2.

    In plain wordsIn one boy, excessive eating was reduced while he took oxytocin alone; the report also covers the later phase with naltrexone.

    Peptide
    Oxytocin
    Outcome
    DecreaseHyperphagia, phase 1
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intranasal · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    reduced hyperphagia during phases 1 and 2
    1 context sentence
    Summary · context
    In this parent-observed study, we tested the administration of intranasal OT for 10 weeks (phase 1), followed by a combination of intranasal OT and NAL for 38 weeks (phase 2) in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia post-CP resection.
  3. 03HumanCase report or seriesEfficacy outcome

    In a boy with hypothalamic obesity, hedonic high-carbohydrate food-seeking in the absence of hunger continued during oxytocin alone (phase 1).

    In plain wordsIn one boy, craving for high-carbohydrate food without hunger continued while he took oxytocin alone.

    Peptide
    Oxytocin
    Outcome
    No significant changeHedonic food-seeking without hunger, phase 1
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intranasal · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    continued hedonic high-carbohydrate food-seeking in the absence of hunger during phases 1 and 2
    1 context sentence
    Summary · context
    In this parent-observed study, we tested the administration of intranasal OT for 10 weeks (phase 1), followed by a combination of intranasal OT and NAL for 38 weeks (phase 2) in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia post-CP resection.

Studies that did not test the peptide alone4

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 04HumanNot a test of Oxytocin aloneCase report or seriesEfficacy outcome

    In a 13-year-old boy with hypothalamic obesity, intranasal oxytocin plus naltrexone lowered the BMI z score from 1.49 to 0.82 over 38 weeks.

    In plain wordsIn one boy with hypothalamic obesity, oxytocin plus naltrexone was followed by a lower BMI z score over 38 weeks.

    Peptide
    Oxytocin
    Outcome
    DecreaseBMI z score change, phase 2
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    BMI z score
    1.49 z score
    start of phase 2
    BMI z score
    0.82 z score
    after 38 weeks of oxytocin plus naltrexone

    Source sentences

    Summary
    reduction in BMI z score from 1.49 to 0.82 over 38 weeks during phase 2
    1 context sentence
    Summary · context
    In this parent-observed study, we tested the administration of intranasal OT for 10 weeks (phase 1), followed by a combination of intranasal OT and NAL for 38 weeks (phase 2) in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia post-CP resection.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 05HumanNot a test of Oxytocin aloneCase report or seriesEfficacy outcome

    In a boy with hypothalamic obesity, hyperphagia was reduced during oxytocin plus naltrexone (phase 2).

    In plain wordsIn one boy, excessive eating was reduced while he took oxytocin plus naltrexone.

    Peptide
    Oxytocin
    Outcome
    DecreaseHyperphagia, phase 2
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    reduced hyperphagia during phases 1 and 2
    1 context sentence
    Summary · context
    In this parent-observed study, we tested the administration of intranasal OT for 10 weeks (phase 1), followed by a combination of intranasal OT and NAL for 38 weeks (phase 2) in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia post-CP resection.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  3. 06HumanNot a test of Oxytocin aloneCase report or seriesEfficacy outcome

    In a boy with hypothalamic obesity, hedonic high-carbohydrate food-seeking in the absence of hunger continued during oxytocin plus naltrexone (phase 2).

    In plain wordsIn one boy, craving for high-carbohydrate food without hunger continued while he took oxytocin plus naltrexone.

    Peptide
    Oxytocin
    Outcome
    No significant changeHedonic food-seeking without hunger, phase 2
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    continued hedonic high-carbohydrate food-seeking in the absence of hunger during phases 1 and 2
    1 context sentence
    Summary · context
    In this parent-observed study, we tested the administration of intranasal OT for 10 weeks (phase 1), followed by a combination of intranasal OT and NAL for 38 weeks (phase 2) in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia post-CP resection.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  4. 07HumanNot a test of Oxytocin aloneCase report or seriesEfficacy outcome

    In a boy with hypothalamic obesity, weight reduction was sustained during decreased parental monitoring and free access to food in the last 10 weeks of oxytocin plus naltrexone.

    In plain wordsIn one boy, weight loss held during the last 10 weeks of oxytocin plus naltrexone, even with less parental monitoring.

    Peptide
    Oxytocin
    Outcome
    DecreaseSustained weight reduction with less parental monitoring
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    sustained weight reduction during decreased parental monitoring and free access to unlocked food in the home during the last 10 weeks of phase 2
    1 context sentence
    Summary · context
    In this parent-observed study, we tested the administration of intranasal OT for 10 weeks (phase 1), followed by a combination of intranasal OT and NAL for 38 weeks (phase 2) in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia post-CP resection.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.